Ultimately, the collaboration is focused on speeding up progress toward a safer and more resilient food system. As Corbion's ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

The invention has made it onto TIME’s 2025 Best Inventions list, in the food and drink category, and would be the first new ...

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...

A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...